Genelux GmbH

Bernried, Germany

Genelux GmbH

Bernried, Germany
SEARCH FILTERS
Time filter
Source Type

This new report includes an updated discussion of approved and clinical stage agents in immuno-oncology, including recently-approved agents. It also addresses the means by which researchers and companies are attempting to build on prior achievements in immuno-oncology to improve outcomes for more patients. Some researchers and companies refer to this approach as immuno-oncology 2.0. The American Society of Clinical Oncology (ASCO), in its 12th Annual Report on Progress Against Cancer (2017), named Immunotherapy 2.0 as its Advance of the Year. Nevertheless, metastatic melanoma remains incurable. Furthermore, in many studies in advanced melanoma and other cancers, only a minority of patients have benefited from immunotherapy treatments. Researchers and companies are therefore looking for ways to build on the initial successes of the immuno-oncology field to improve outcomes for more patients, hence the need for an immuno-oncology 2.0.  Agents that are intended to improve the results of treatment with agents like checkpoint inhibitors may also be referred to as second-wave immuno-oncology agents. As discussed in this report, researchers have found that checkpoint inhibitors produce tumor responses by reactivating TILs (tumor infiltrating lymphocytes)-especially CD8+ cytotoxic T cells. This key observation is perhaps the most important factor driving development of second-wave immuno-oncology strategies. As a result, researchers have been developing biomarkers that distinguish inflamed (i.e., TIL-containing) tumors-which are susceptible to checkpoint inhibitor therapy-from cold tumors, which are not. They have also been working to develop means to render cold tumors inflamed, via treatment with various conventional therapies and/or development of novel agents. These studies are the major theme of second-wave immuno-oncology, or immuno-oncology 2.0. Highlights of this Report Include: - Approvals of checkpoint inhibitors - Biomarkers for checkpoint inhibitor treatments - Approved and clinical-stage immunotherapy biologics other than checkpoint inhibitors - Immunotherapy with TIL cells - Commercialization of TIL therapy - Adoptive immunotherapy with genetically engineered T cells bearing chimeric antigen receptors (CARs) - Manufacturing issues with CAR T-cell therapies - General conclusions on the progress of cellular immunotherapy - Outlook for cancer immunotherapy Key Topics Covered: 1: Introduction - The early history of cancer immunotherapy - Coley's toxins - Cytokines as immunomodulatory drugs - Interleukin-2 - Alpha-interferons - Interleukin-12 - Interleukin-12 as a bridge between innate and adaptive immunity - Investigation of interleukin-12 as an anticancer therapeutic - Interleukin-10 - Interleukin-15 - Admune/Novartis' heterodimeric IL-15:IL-15Ra (hetIL-15) - Altor's ALT-803 - Conclusions: Cytokine-based immunotherapies for cancer 2: What are immune checkpoints? - CTLA-4 blocking agents - Ipilimumab - Tremelimumab - PD-1 blocking agents - Nivolumab - Combination therapy of nivolumab plus ipilimumab in melanoma - Pembrolizumab - Pembrolizumab as a first-line treatment for advanced NSCLC - Pembrolizumab in colorectal carcinoma with mismatch-repair deficiency - Studies of pembrolizumab in combination immunotherapies - PDR001 - PD-L1 blocking agents - Atezolizumab - Atezolizumab in treatment of urothelial carcinoma - Atezolizumab for the treatment of NSCLC - Atezolizumab in treatment of other solid tumors - Other anti-PD-L1 mAb agents - Durvalumab - Avelumab - Anti-LAG-3 agents - anti-TIM-3 - NewLink Genetics' small-molecule IDO pathway inhibitors and checkpoint inhibition - Infinity's PI3K? inhibitor IPI-549 for modulation of immune suppression in tumors - Biomarkers for checkpoint inhibitor treatments - Target biomarkers - Genetic biomarkers - Immunological biomarkers - Use of biomarker tests in treatment with checkpoint inhibitors - Checkpoint inhibitors plus radiation therapy - Checkpoint inhibitors plus targeted therapies - Checkpoint inhibitors with cytotoxic chemotherapies - Discussion 3: Immune Agonists - Celldex Therapeutics' Varlilumab (CDX-1127) - OX40 agonists - MedImmune/AZ's OX40 agonist program - Roche/Genentech's OX40 agonist program - Nektar Therapeutics/BMS's NKTR-214, a CD122 agonist - Glucocorticoid-induced TNFR-related (GITR) protein agonist (Leap Therapeutics' TRX518) - Conclusions 4: Bispecific antibodies - Marketed bispecific antibody agents - Catumaxomab - Blinatumomab - Bispecific antibodies as an alternative to CAR-T cells - Xencor's cross-linking monoclonal antibody (XmAb) bispecific platform technology - Regeneron's native human immunoglobulin-format bsAb, REGN1979 - Roche/Genentech's full-length bsAbs: Generated using CrossmAb technology - MacroGenics' MGD007: Generated using dual-affinity re-targeting (DART) technology - Conclusions 5: Therapeutic Anticancer Vaccines and Oncolytic viruses - Introduction - Cancer vaccines-a field rife with clinical failures - Why has the cancer vaccine field been so prone to clinical failure? - Marketed therapeutic cancer vaccines and oncolytic virus therapies - Dendreon/Valeant's sipuleucel-T - Amgen's talimogene laherparepvec (T-Vec)/Imlygic - Therapeutic cancer vaccines and oncolytic virus therapies in clinical development - Celldex's CDX-1401 - Bavarian Nordic's PROSTVAC-VF - Argos Therapeutics' AGS-003 - Sydys Corporation's CVac - Aduro Biotech's CRS-207 - TapImmune's TPIV110 HER2/neu and TPIV200 folate receptor alpha multi-epitope vaccines - Genelux's GL-ONC1 oncolytic virus - Conclusions 6: Adoptive Immunotherapy for Cancer - Introduction - Adoptive immunotherapy with tumor infiltrating lymphocytes - A specific immunodominant mutation in a melanoma patient who had a durable complete remission due to TIL therapy - Adoptive immunotherapy based on mutation-specific CD4+ T cells in an epithelial cancer - Successful targeting of KRAS G12D via adoptive immunotherapy in a case of metastatic colorectal cancer - Dr. Rosenberg's recent studies on neoantigen-reactive TILs for use in adoptive cellular immunotherapy - Commercializing TIL therapy - Adoptive immunotherapy with genetically engineered T cells bearing chimeric antigen receptors (CARs) - Leading clinical programs in CAR T-cell based immunotherapy - Kite Pharma's KTE-C19 (axicabtagene ciloleucel) - Novartis' CTL019 - Juno's JCAR015 and other Juno anti-CD19 CARs - Other CAR T-cell therapies that target hematologic malignancies - bluebird bio's bb2121 for multiple myeloma - CAR T-cell therapies that target solid tumors - Novartis/University of Pennsylvania's CARTmeso - EGFRvIII CAR T-cell therapies - Companies developing engineered improvements in CAR T-cell therapy - Bellicum Pharmaceuticals' technologies for modulation of CAR T-cell therapies - Cellectis' technologies for design and manufacture of off-the shelf CAR T-cell therapies - Manufacturing issues with CAR T-cell therapies - Can bispecific antibodies be competitive with CAR T-cell therapies? - Adptimmune recombinant TCR clinical candidates - Kite Pharma recombinant TCR program - Juno Therapeutics' recombinant TCR program - Recombinant TCR studies at the NCI - Conclusions - Market size estimates for the T-cell therapy market 7: General Conclusions - Major theme of this report: Immuno-oncology 2.0 or second-wave immuno-oncology - Approvals of checkpoint inhibitors - Biomarkers for checkpoint inhibitor treatments - Approved and clinical-stage immunotherapy biologics other than checkpoint inhibitors - Immunotherapy with TIL cells - Commercialization of TIL therapy - Adoptive immunotherapy with genetically engineered T cells bearing chimeric antigen receptors (CARs) - Manufacturing issues with CAR T-cell therapies - Adoptive immunotherapy via autologous recombinant TCR technology - General conclusions on the progress of cellular immunotherapy - Insight Pharma Reports survey on cancer immunotherapy - Outlook for cancer immunotherapy For more information about this report visit http://www.researchandmarkets.com/research/rkf8pp/cancer Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-cancer-immunotherapy-report-2017-building-on-initial-successes-to-improve-clinical-outcomes---research-and-markets-300441006.html


The scope of this report covers current cancer immunotherapy markets for most common cancers. The market segments included in this report are therapeutic monoclonal antibodies (with special focus on checkpoint inhibitors), synthetic interleukins, interferons, and colony-stimulating factors; small kinase inhibitors of cancer-related targets; protective and therapeutic cancer vaccines; and adoptive cell therapies. This report also covers treatments that are in development for late-stage and early-stage oncolytic viruses. Detailed epidemiological information, discussion of incidence and mortality trends, overview of regulatory landscapes, and analysis of market shares for leading products and companies are also included in this report. 1: Introduction - Goals and Objectives - Reasons for Doing This Study - Intended Audience - Scope of The Study - Information Sources for the Technology Assessment - Forecasting Methodology - Geographic Breakdown 3: Overview - Past and Present of Cancer Immunology - What is Cancer? - Treating Cancer - Challenges in Treating Cancer - Cancer and the Immune System - Immunotherapy - Towards Combination Immunotherapy - Focusing on Cell-mediated Adaptive Immunity - Fine Tuning Versus Boosting Cancer Immunity - Early Versus Advanced Stage Cancer Immunotherapy - Personalized Treatment Paradigm - Clinically Significant Types of Cancers - Future of Checkpoint Inhibitors, Cancer Vaccines, and Oncolytic Virology 4: Overview of Cancer Immunotherapy - Immune System and Immunotherapy - Therapeutic Monoclonal Antibodies - Checkpoint Inhibitors - Biological Response Modifiers - Vaccines - Other - Expanded Information on Selected Product Candidates and Recent Regulatory Applications 7: Company Profiles - Abbvie Inc. - Adaptimmune - Aduro Biotech - Advantagene - Advaxis Immunotherapies - Amgen - Argos Therapeutics - Ariad Pharmaceuticals - Arog Pharmaceuticals - Aserta Pharmaceuticals - Astellas - Astrazeneca - Avax Technologies - Bavarian Nordic - Bayer Healthcare - Biovex - Boehringer Ingelheim - Boston Biomedical - Bristol-Myers Squibb - Cell Medica - Celldex Therapeutics - Celgene Corp. - Chugai - Cold Genesys - Daiichi Sankyo Co. - Dendreon - Dnatrix - Eisai - Eli Lilly - F Hoffmann La Roche AG - Genelux - Gilead Sciences Inc. - Glaxosmithkline Plc - Hanmi Pharmaceutical - Heat Biologics - Immune Design - Immunocellular Therapeutics Ltd. - Immunomedics Inc. - Immunovaccine Inc. - Immunovative Therapies - Incyte Ciorp. - Inovio Pharmaceuticals Inc. - Janssen Pharmaceuticals - Kadmon Pharmaceuticals Corp. - Kite Pharmaceuticals Inc. - Kyowa Hakko Kirin Co. Ltd. - Ligand Pharmaceuticals Inc. - Lion Biotechnologies - Lokon Pharmaceuticals AB - Medimmune - Merck & Co. - Merck Kgaa - Merck Serono - Medigene AG - Mirati Therapeutics - Multivir Inc. - Newlink Genetics - Northwest Biotherapeutics - Novartis Pharma Services AG - Oncolys Biopharma Inc. - Oncolytics Biotech Inc. - Oncomed Pharmaceuticals Inc. - Oncos Therapeutics Ltd. - Ono Pharmaceutical Co. - Otsuka Pharmaceutical Co., Ltd. - Pfizer Inc. - Plexxikon Inc. - Portola Pharmaceuticals Inc. - Provectus Biopharmacueticals Inc. - Psioxus Therapeutics Ltd. - Sanofi SA - Seattle Genetics - Shanghai Sunway Biotech Co. Ltd. - Shenzhen Sibiono Gentech - Sillajen Biotherapeutics Inc. - Spectrum Pharmaceuticals - Takara Bio Inc. - Takeda Co. Ltd. - Tapimmune Inc. - Targovax - Teva Pharmaceutical Industries Ltd. - TG Therapeutics Inc. - Tracon Pharmaceuticals Inc. - Transgene - VCN Biosciences - Ventirx - Verastem Inc. - Viralytics Ltd. - Virttu Biologics Ltd - Vyriad - Western Oncolytics Ltd. For more information about this report visit http://www.researchandmarkets.com/research/fpck42/cancer_immunology To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-cancer-immunology-and-oncolytic-virology-technologies-and-markets-report-2017-market-should-reach-965-billion-by-2021-from-730-billion-in-2016-at-a-cagr-of-57---research-and-markets-300458203.html

Loading Genelux GmbH collaborators
Loading Genelux GmbH collaborators